Prof Jesús San-Miguel talks about the progression in myeloma survival rates and the contributing factors. Data from a large randomised trial is showing that zoledronic acid compared to oral clodronate is superior in preventing skeletal complications and is associated with prolongation of survival. (In Spanish)

This interview is supported by an unrestricted educational grant from Novartis Oncology.